# Ravulizumab and COVID-19

> **NCT04570397** · PHASE3 · UNKNOWN · sponsor: **Brigham and Women's Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Covid19
- Thrombotic Microangiopathies
- Acute Kidney Injury

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT04570397
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-18
- **Primary completion:** 2023-05
- **Final completion:** 2023-11
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570397, "Ravulizumab and COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04570397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*